Advertisement

Antiproliferative Effect of Trapidil on a PDGF-Producing Glioma Cell Line In Vivo

  • Jun-ichi Kuratsu
  • Shuichi Takaki
  • Yosuke Mihara
  • Masato Kochi
  • Yukitaka Ushio

Abstract

Cell proliferation is regulated by growth factors which stimulate mitogenicity through binding to specific receptors on target cells. The platelet-derived growth factor (PDGF) is produced by many kinds of cells.

Keywords

Tumor Weight U251MG Cell Malignant Glioma Cell Line U105MG Tumor Myointimal Hyperplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kuratsu J, Ushio Y (1990) Antiproliferative effect of Trapidil, platelet-derived growth factor antagonist, on a glioma line in vitro. J Neurosurg 73: 436–440PubMedCrossRefGoogle Scholar
  2. 2.
    Kuratsu J, Estes JE, Yokota S, Mahaley MS Jr, Gillespie GY (1989) Growth factors derived from a human malignant glioma cell line, U-251MG. J Neurooncol 7: 225–236PubMedCrossRefGoogle Scholar
  3. 3.
    Ohnishi H, Yamaguchi K, Shimada S, Suzuki Y, Kumagai A (1981) A new approach to the treatment of atherosclerosis and Trapidil as an antagonist to platelet-derived growth factor. Life Sci 28: 1641–1646PubMedCrossRefGoogle Scholar
  4. 4.
    Ohnishi H, Yamaguchi K, Shimada S, Suzuki Y, Saito Y, Kumagai A (1981) Growth-promoting activity of platelet-derived growth factor ( PDGF) and effect of Trapidil. J Jpn Coll Angiol 21: 409–414Google Scholar
  5. 5.
    Tiell ML, Sussman II, Gordon PB, Sanders RN (1983) Suppression of fibroblast proliferation in vitro and of myointimal hyperplasia in vivo by the triazolopyrimidine, Trapidil. Artery 12: 33–50Google Scholar
  6. 6.
    Takamiya Y, Kohsaka S, Toya S, Otani M, Mikoshiba K, Tsukada Y (1986) Possible association of platelet-derived growth factor ( PDGF) with the appearance of reactive astrocytes following brain injury in situ. Brain Res 383: 305–309PubMedCrossRefGoogle Scholar
  7. 7.
    Cho KG, Hoshino T, Nagashima T, Murovic JA, Wilson CB (1984) Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling. J Neurosurg 65: 790–794Google Scholar
  8. 8.
    Hoshino T, Nagashima T, Murovic JA, Edwards MSB, Gutin PH, Davis RL, DeArmond SJ (1986) In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling. J Neurosurg 64: 453–459PubMedCrossRefGoogle Scholar
  9. 9.
    Leof EB, Van Wyk JJ, O’Keefe EJ, Pledger WJ (1983) Epidermal growth factor (EGF) is required only during the transverse of early G1 in PDGF-stimulated density-arrested BALB/c-3T3 cells. Exp Cell Res 147: 202–208PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1991

Authors and Affiliations

  • Jun-ichi Kuratsu
  • Shuichi Takaki
  • Yosuke Mihara
  • Masato Kochi
  • Yukitaka Ushio
    • 1
  1. 1.Department of NeurosurgeryKumamoto University Medical SchoolKumamoto, 860Japan

Personalised recommendations